7,425 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Worldquant Millennium Advisors LLC

Worldquant Millennium Advisors LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,425 shares of the biotechnology company’s stock, valued at approximately $247,000.

Other hedge funds have also recently modified their holdings of the company. Blue Trust Inc. raised its position in shares of Exelixis by 134.7% during the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 8,208 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Exelixis in the 4th quarter valued at $17,046,000. Allspring Global Investments Holdings LLC lifted its holdings in Exelixis by 82.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after purchasing an additional 704,786 shares in the last quarter. Inspire Investing LLC lifted its holdings in Exelixis by 25.0% in the 4th quarter. Inspire Investing LLC now owns 36,659 shares of the biotechnology company’s stock valued at $1,221,000 after purchasing an additional 7,331 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its holdings in Exelixis by 4.6% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 505,289 shares of the biotechnology company’s stock valued at $16,826,000 after purchasing an additional 22,225 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In other news, Director Tomas J. Heyman sold 4,544 shares of the company’s stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $44.29, for a total value of $201,253.76. Following the transaction, the director now directly owns 32,470 shares in the company, valued at approximately $1,438,096.30. This represents a 12.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Patrick J. Haley sold 126,383 shares of the company’s stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the completion of the transaction, the executive vice president now owns 446,459 shares in the company, valued at approximately $21,412,173.64. This represents a 22.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 559,873 shares of company stock worth $24,646,347 over the last quarter. 2.82% of the stock is currently owned by company insiders.

Exelixis Stock Down 2.0%

NASDAQ:EXEL opened at $42.86 on Friday. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $48.85. The company has a market capitalization of $11.69 billion, a P/E ratio of 24.21, a P/E/G ratio of 1.13 and a beta of 0.25. The stock’s fifty day moving average is $37.79 and its two-hundred day moving average is $36.08.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on EXEL shares. Morgan Stanley restated an “overweight” rating and issued a $47.00 price objective (up previously from $40.00) on shares of Exelixis in a report on Wednesday, May 14th. Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $41.00 to $33.00 in a report on Friday, January 24th. UBS Group restated an “underperform” rating on shares of Exelixis in a report on Thursday, April 17th. Guggenheim set a $45.00 target price on Exelixis and gave the stock a “buy” rating in a report on Thursday, May 15th. Finally, Wells Fargo & Company restated a “market outperform” rating on shares of Exelixis in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Exelixis has an average rating of “Moderate Buy” and a consensus price target of $38.94.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.